Evidence map›Paper›PMID 42535141›Full record

ArticleGastroenterology and hepatology from bed to bench2026

Stage analysis of gastric cancer: a bioinformatic approach.

Fatemeh Montazer, Mostafa Rezaei-Tavirani, Babak Arjmand, Nastaran Asri, Zahra Razzaghi, Farideh Razi, Fatemeh Bandarian

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastroenterology and hepatology from bed to bench, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fatemeh MontazerDepartment of Pathology, Associated Professor of Pathology, School of Medicine, Iran University of Medical Sciences (IUMS), Tehran, Iran.
Mostafa Rezaei-TaviraniProteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Babak ArjmandHematology-Oncology and Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology, and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran.
Nastaran AsriCeliac Disease and Gluten Related Disorders Research Center, Research Institute for Gastroenterology and Liver Disease, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zahra RazzaghiLaser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Farideh RaziDiabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Fatemeh BandarianEndocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Analysis of stage transition in gastric cancer is the aim of this project. Background: Gastric cancer, as a lethal digestive cancer, is classified based on tumor, node, and metastasis. Early detection of gastric cancer facilitates cancer management and treatment. Methods: Data on gene expression changes at different stages of gastric cancer are extracted from the Gene Expression Omnibus (GEO) database and evaluated using the GEO2R program to identify significantly differentially expressed genes (DEGs). The queried DEGs were enriched via Gene Ontology to explore dysregulated pathways. The crucial DEGs were identified via directed protein-protein interaction (PPI) analysis. Results: Analyses revealed that stage IA → stage IIA and stage IB → stage IIB transitions in gastric cancer are accompanied by considerable numbers of significant DEGs. MYC, "Nitric oxide metabolism in cystic fibrosis", and "Hepatitis C and hepatocellular carcinoma" are the critical dysregulate gene and pathways in the stage IB → stage IIB transition. ACTG2, MYH11, CDKN2A, MS4A2, and FCER1A were pointed out as the critical genes in the IA → IIA stage transition. Conclusion: In conclusion, inhibition of MYC was introduced as a crucial point in preventing the stage IB → stage IIB transition, and "Smooth muscle damage" was identified as a key process in stage IA → stage IIA transition. Experimental validation is recommended to find the applicable findings.

Indexed as

Gastric cancerGeneNetwork analysisPathwayStaging

Identifiers

PMID42535141
PMCPMC13423315

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.